CD44 expression and axillary lymph node metastasis in infiltrating ductal carcinoma of the breast.

Lai Meng Looi, Phaik Leng Cheah, Wenran Zhao, Min Hwei Ng, Cheng Har Yip

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Metastasising ability connotes one of the most important life-threatening properties of malignant neoplasms. Recent studies indicate that CD44 proteins, multifunctional cell adhesion molecules which contribute to "homing" of lymphocytes to lymph nodes as well as cell-cell and cell-matrix interactions, are potential markers of tumour progression. However, whether CD44 expression by human tumours contribute to increased metastatic risk remains controversial. In an attempt to clarify its role in breast cancer, we have investigated the correlation between CD44 expression by breast carcinoma and the presence of axillary lymph node metastases. CD44 expression was detected using a standard immunoperoxidase method on formalin-fixed, paraffin-embedded, primary infiltrating ductal breast carcinoma tissues taken from 60 female patients who underwent mastectomy with axillary node clearance. Tumours were graded according to the modified Bloom and Richardson criteria. 62% of patients had histologically-proven lymph node metastasis. 40% of primary cancers exhibited cytoplasmic membrane immunopositivity for CD44. 46% of primary tumours which have metastasied to axillary lymph nodes were CD44 positive whereas 30% of tumours which have not metastasised expressed CD44. CD44 positivity was expressed by 20% of grade 1, 31% grade 2 and 58% grade 3 tumours. Our results suggest that CD44 may have a role in the progression of breast cancer and emphasise the need to investigate its interaction with other mechanisms of cancer advancement.

Original languageEnglish
Pages (from-to)83-86
Number of pages4
JournalThe Malaysian journal of pathology
Volume28
Issue number2
Publication statusPublished - Dec 2006
Externally publishedYes

Fingerprint

Carcinoma, Ductal, Breast
Lymph Nodes
Neoplasm Metastasis
Neoplasms
Breast Neoplasms
Mastectomy
Cell Adhesion Molecules
Tumor Biomarkers
Cell Communication
Paraffin
Formaldehyde
Cell Membrane
Lymphocytes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

CD44 expression and axillary lymph node metastasis in infiltrating ductal carcinoma of the breast. / Looi, Lai Meng; Cheah, Phaik Leng; Zhao, Wenran; Ng, Min Hwei; Yip, Cheng Har.

In: The Malaysian journal of pathology, Vol. 28, No. 2, 12.2006, p. 83-86.

Research output: Contribution to journalArticle

Looi, Lai Meng ; Cheah, Phaik Leng ; Zhao, Wenran ; Ng, Min Hwei ; Yip, Cheng Har. / CD44 expression and axillary lymph node metastasis in infiltrating ductal carcinoma of the breast. In: The Malaysian journal of pathology. 2006 ; Vol. 28, No. 2. pp. 83-86.
@article{6f15af025f644d12b66a4707dcfe4224,
title = "CD44 expression and axillary lymph node metastasis in infiltrating ductal carcinoma of the breast.",
abstract = "Metastasising ability connotes one of the most important life-threatening properties of malignant neoplasms. Recent studies indicate that CD44 proteins, multifunctional cell adhesion molecules which contribute to {"}homing{"} of lymphocytes to lymph nodes as well as cell-cell and cell-matrix interactions, are potential markers of tumour progression. However, whether CD44 expression by human tumours contribute to increased metastatic risk remains controversial. In an attempt to clarify its role in breast cancer, we have investigated the correlation between CD44 expression by breast carcinoma and the presence of axillary lymph node metastases. CD44 expression was detected using a standard immunoperoxidase method on formalin-fixed, paraffin-embedded, primary infiltrating ductal breast carcinoma tissues taken from 60 female patients who underwent mastectomy with axillary node clearance. Tumours were graded according to the modified Bloom and Richardson criteria. 62{\%} of patients had histologically-proven lymph node metastasis. 40{\%} of primary cancers exhibited cytoplasmic membrane immunopositivity for CD44. 46{\%} of primary tumours which have metastasied to axillary lymph nodes were CD44 positive whereas 30{\%} of tumours which have not metastasised expressed CD44. CD44 positivity was expressed by 20{\%} of grade 1, 31{\%} grade 2 and 58{\%} grade 3 tumours. Our results suggest that CD44 may have a role in the progression of breast cancer and emphasise the need to investigate its interaction with other mechanisms of cancer advancement.",
author = "Looi, {Lai Meng} and Cheah, {Phaik Leng} and Wenran Zhao and Ng, {Min Hwei} and Yip, {Cheng Har}",
year = "2006",
month = "12",
language = "English",
volume = "28",
pages = "83--86",
journal = "Malaysian Journal of Pathology",
issn = "0126-8635",
publisher = "Malaysian Society of Pathologists",
number = "2",

}

TY - JOUR

T1 - CD44 expression and axillary lymph node metastasis in infiltrating ductal carcinoma of the breast.

AU - Looi, Lai Meng

AU - Cheah, Phaik Leng

AU - Zhao, Wenran

AU - Ng, Min Hwei

AU - Yip, Cheng Har

PY - 2006/12

Y1 - 2006/12

N2 - Metastasising ability connotes one of the most important life-threatening properties of malignant neoplasms. Recent studies indicate that CD44 proteins, multifunctional cell adhesion molecules which contribute to "homing" of lymphocytes to lymph nodes as well as cell-cell and cell-matrix interactions, are potential markers of tumour progression. However, whether CD44 expression by human tumours contribute to increased metastatic risk remains controversial. In an attempt to clarify its role in breast cancer, we have investigated the correlation between CD44 expression by breast carcinoma and the presence of axillary lymph node metastases. CD44 expression was detected using a standard immunoperoxidase method on formalin-fixed, paraffin-embedded, primary infiltrating ductal breast carcinoma tissues taken from 60 female patients who underwent mastectomy with axillary node clearance. Tumours were graded according to the modified Bloom and Richardson criteria. 62% of patients had histologically-proven lymph node metastasis. 40% of primary cancers exhibited cytoplasmic membrane immunopositivity for CD44. 46% of primary tumours which have metastasied to axillary lymph nodes were CD44 positive whereas 30% of tumours which have not metastasised expressed CD44. CD44 positivity was expressed by 20% of grade 1, 31% grade 2 and 58% grade 3 tumours. Our results suggest that CD44 may have a role in the progression of breast cancer and emphasise the need to investigate its interaction with other mechanisms of cancer advancement.

AB - Metastasising ability connotes one of the most important life-threatening properties of malignant neoplasms. Recent studies indicate that CD44 proteins, multifunctional cell adhesion molecules which contribute to "homing" of lymphocytes to lymph nodes as well as cell-cell and cell-matrix interactions, are potential markers of tumour progression. However, whether CD44 expression by human tumours contribute to increased metastatic risk remains controversial. In an attempt to clarify its role in breast cancer, we have investigated the correlation between CD44 expression by breast carcinoma and the presence of axillary lymph node metastases. CD44 expression was detected using a standard immunoperoxidase method on formalin-fixed, paraffin-embedded, primary infiltrating ductal breast carcinoma tissues taken from 60 female patients who underwent mastectomy with axillary node clearance. Tumours were graded according to the modified Bloom and Richardson criteria. 62% of patients had histologically-proven lymph node metastasis. 40% of primary cancers exhibited cytoplasmic membrane immunopositivity for CD44. 46% of primary tumours which have metastasied to axillary lymph nodes were CD44 positive whereas 30% of tumours which have not metastasised expressed CD44. CD44 positivity was expressed by 20% of grade 1, 31% grade 2 and 58% grade 3 tumours. Our results suggest that CD44 may have a role in the progression of breast cancer and emphasise the need to investigate its interaction with other mechanisms of cancer advancement.

UR - http://www.scopus.com/inward/record.url?scp=42449088999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42449088999&partnerID=8YFLogxK

M3 - Article

VL - 28

SP - 83

EP - 86

JO - Malaysian Journal of Pathology

JF - Malaysian Journal of Pathology

SN - 0126-8635

IS - 2

ER -